Skip to main content

Perspective Therapeutics, Inc.

corporate_fare Company Profile

Perspective Therapeutics, Inc.

CATX·NYSE·Life Sciences·CIK 0000728387

Perspective Therapeutics, Inc. is a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body. It has proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212 Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties. The company is also developing complementary imaging diagnostics that incorporate the same targeting moieties, which provides the opportunity to personalize treatment and optimize patient outcomes. This theranostic approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity. Its neuroendocrine tumor (VMT-α-NET), melanoma (VMT01) and solid tumor (PSV359) programs are in Phase 1/2a imaging and therapy trials in the U.S. The company is growing its regional network of drug product candidate finishing facilities, enabled by its proprietary 212 Pb generator technologies, to deliver patient-ready product candidates for clinical trials and commercial operations. Its goal is to advance innovative precision medicines for the treatment of cancer by developing and commercializing its precision targeted alpha therapies (TATs). Key elements of its strategy include discovering and developing a broad oncology pipeline: advancing its initial drug candidate, VMT-α-NET, through clinical development for the treatment of neuroendocrine tumors expressing somatostatin receptor type 2 (SSTR2); expanding the potential of its product candidates in additional indications and as combination therapies in current and additional indications; advancing its second drug candidate, VMT01, through clinical development for the treatment of melanoma tumors expressing melanocortin 1 receptor (MC1R); and advancing its third drug candidate, PSV359, through clinical development for the treatment of solid tumors expressing fibroblast activation protein. It also aims to deploy its innovative platform technology by continuing to leverage its TAT platform to expand its pipeline of product candidates and utilizing a precision medicine approach by leveraging imaging diagnostics, and to build and strengthen its manufacturing and supply infrastructure by continuing to strengthen and scale its internal manufacturing capabilities.

Perspective Therapeutics, Inc. (NYSE:CATX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 3 items for CATX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-09, rated 7/10. Across its 3 most recent items scored 7 or higher, the top rating is 7/10. Recent SEC coverage for CATX spans 8-K.

Recent high-impact activity:

  • Perspective Q3 2026: $202M Cash Into 2028, PSV359 Fast Track, Merck Collaboration
  • Perspective Reports 75% Disease Control at 3.0 mCi in Heavily Pretreated Melanoma
  • Perspective's VMT-α-NET Shows 75% 18-Month PFS in SSTR2+ GEP-NETs; End-of-Phase 2 Targeted 1Q 2027

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$103.12M
Diluted EPS
-$1.40
Op. Cash Flow
-$82.48M
Free Cash Flow
-$95.23M
Operating Income
-$113.56M
Cash & Equivalents
$30.63M
Debt / Equity
0.00×
Shares Outstanding
74.34M sh
Source: 10-K · filed 2026-03-16 · accession 0000728387-26-000004

Short Interest & Short Volume

2.47 days to cover

FINRA reported short interest of 8,974,834 shares in CATX as of the October 30, 2026 settlement, a 46.2% decrease from the prior period — about 2.5 days to cover at its recent average daily volume. On November 20, 2026, 57.0% of CATX volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)8,974,834 shares as of October 30, 2026
Change vs prior period▼ 46.2%
Days to cover2.47 at avg daily volume of 3,629,551
Daily short volume (FINRA facilities)57.0% of 747,702 shares on November 20, 2026
5-day average short volume54.3%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

$0.75 -0.50% today
52-week range · as of 2026-11-09 $0.75 – $6.16
Market cap
$91.03M
Volume
1.4M (0.4× avg)
3-mo avg 3.5M
Live data · 2026-11-22 12:33 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed CATX - Latest Insights

CATX
Nov 09, 2026, 4:33 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.860
Real-time Price: $0.750 info
Change: -$0.110 (-13%) info
Market Cap: $91.028M info
CATX
Nov 06, 2026, 12:05 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.85005
Real-time Price: $0.750 info
Change: -$0.10005 (-12%) info
Market Cap: $91.028M info
CATX
Nov 06, 2026, 7:00 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.8199
Real-time Price: $0.750 info
Change: -$0.0699 (-9%) info
Market Cap: $91.028M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets